Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias

Next Previous
Trial Profile

A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alisertib (Primary)
  • Indications Acute myeloid leukaemia; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Liver cancer; Neuroblastoma; Osteosarcoma; Precursor cell lymphoblastic leukaemia-lymphoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Urogenital cancer; Wilms' tumour
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use

Most Recent Events

  • 25 Aug 2021 Results of a population pharmacokinetic and exposure-safety analyses of alisertib in children enrolled in two clinical trials (NCT02444884 and NCT01154816) published in the Journal of Clinical Pharmacology
  • 18 Feb 2019 Results evaluating efficacy of alisertib in pediatric patients with refractory or recurrent solid tumors or acute leukemias published in the Clinical Cancer Research
  • 21 Sep 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top